Aminologics

아미노로직스 · 074430

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$68.1M (₩94B)

Overview

Aminologics makes active pharmaceutical ingredients, the raw chemical substances that finished-drug manufacturers use to produce medicines, covering areas such as stroke treatment, eye disease, skin conditions, and cosmetics.

It also manufactures and supplies amino acid derivative compounds. The company supplies these ingredients to domestic Korean pharmaceutical companies that produce finished drugs, placing it upstream in the Korean drug supply chain. Aminologics is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$16M

▲ +31.2% YoY

Operating profit · FY2025

US$2.6M

Turned profitable

Net income · FY2025

US$2.6M

Turned profitable

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$15.1M(₩20.9B)	US$12.2M(₩16.8B)	US$16M(₩22B)
Operating profit	US$1.1M(₩1.5B)	−US$1.6M(−₩2.2B)	US$2.6M(₩3.6B)
Net income	US$1.8M(₩2.4B)	−US$1.2M(−₩1.6B)	US$2.6M(₩3.5B)

Revenue

FY2023US$15.1M
FY2024US$12.2M
FY2025US$16M

Operating profit

FY2023US$1.1M
FY2024−US$1.6M
FY2025US$2.6M

Net income

FY2023US$1.8M
FY2024−US$1.2M
FY2025US$2.6M

Key ratios (FY2025)

ROE

6.3%

Debt/Eq

50.3%

Op. margin

16.3%

Net margin

16.0%

Rev. YoY

▲ +31.2%

Why it matters

The Korean pharmaceutical industry is heavily regulated by the government at every stage, from approval and pricing to manufacturing, distribution, and supply, which shapes the operating environment for all domestic ingredient suppliers.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?